How your money helps

Nfa logo
Epilepsy Action logo

Epilepsy Action

Epilepsy Action logoFor the 75 people in the UK who are diagnosed with epilepsy every single day it can be a distressing and disturbing time, a time when they have many questions to ask but find very few avenues to find the answers. Epilepsy Action can fill this gap by providing advice and support in a number of ways.

What we do

Epilepsy Action is the largest member-led epilepsy epilepsy in Britain, acting as the voice for the UK's estimated 456,000 people with epilepsy, as well as their friends, families, carers, health professionals and the many other people on whose lives the condition has an impact.

We support people with epilepsy through our

We publish

We provide information to anyone interested in epilepsy, in the form of

and we offer

We campaign to

with campaigns like

We fund research

The Neurofibromatosis AssociationThe Neurofibromatosis Association

The Neurofibromatosis Association (NfA) is the only UK charity dedicated to the provision of support for those affected by either neurofibromatosis type 1 (Nf1) or neurofibromatosis type 2 (Nf2), their families and the professionals concerned with their care.  Although they share some similar characteristics the conditions are, in fact, two separate genetic disorders and there is still, understandably, some confusion over both their similarities and their differences.

Neurofibromatosis type 1 was first described by von Recklinghausen in 1882 and was originally named after him.  It affects 1 in every 2,500 people world-wide and some 24,000 in this country alone.  Complications include learning difficulties, behavioural problems, large benign skin tumours, and internal spine and brain tumours; there is also an increased risk of epilepsy.  While only recognised as a condition about 120 years ago, a 2,000 year old Greek statue shows the visible ‘lumps and bumps’ that are so characteristic.  It is almost certain that Victor Hugo’s Quasimodo, the Hunchback of Notre Dame, was affected by Nf1 and it may be that the author also had the disorder.

Neurofibromatosis type 2 is seldom diagnosed until loss of hearing has occurred and, by that time, those affected are in their late teens or early twenties.  First described in 1822 (Wishart), while an affected person may have some visible neurofibromas on their skin, most of the benign tumours form in the brain or on the spinal cord; the main diagnostic feature are bi-lateral vestibular Schwannomas (tumours on the nerve of balance) which, as they grow, affect a person’s hearing. 

There is, as yet, no effective drug treatment for either condition and, in most instances, the only relief from symptoms is surgery.

The Neurofibromatosis Association was formed in 1982 to provide help, support and advice not only for those affected but also their families and the professionals involved in their care. 

What we do

  • We employ a network of hospital-based professionals who help co-ordinate the care and treatment of those with either Nf1 or Nf2.   Quite apart from visits to their GPs, often those affected by either condition need to be seen by a range of specialists from different hospital departments – genetics, ophthalmology, dermatology, orthopaedics, plastic and maxillo-facial surgery among others.  Our Support Co-ordinators are able to liaise between all the individuals concerned, especially when the concerned patient – or their family – have questions and problems arising from their condition;

  • We provide a telephone helpline

  • We provide relevant and specific literature for patients and the professionals involved in their care; there are three issues a year of the NfA newsletter.  Publications on neurofibromatosis include:

Neurofibromatosis Type 1

  • Clinical guidelines for the management of individuals with Nf1 (for professionals)

  • Nf1 – a guide for families who have a new diagnosis

  • The newly diagnosed child with Nf1 – a guide for parents

  • The child with Nf – a guide for health professionals

  • Talking to children about neurofibromatosis

  • Nf1 – information for teachers

  • ‘Achieving in spite of ….’ – a booklet on specific learning difficulties

  • Examples of the problems experienced by some children with Nf1 and learning    difficulties

  • Challenging behaviour

  • Developmental co-ordination disorder

  • Disorders of bone growth and soft tissue changes

  • Congenital pseudarthrosis

  • Nf1 and scoliosis

  • ‘Polly’s best friend’ by Gina Malyon (for girls under 10)

  • ‘The winning goal’ by Gina Malyon (for boys under 10)

Neurofibromatosis Type 2

  • Neurofibromatosis Type 2 – information for patients and professionals

  • Neurofibromatosis Type 2 – information for patients

  • Communication and Nf2

  • Coping with fatigue in Nf2

  • Help with speech difficulties in Nf2

  • Stereotactic radiosurgery and radiotherapy for Nf2 vestibular Schwannomas

  • The auditory brainstem implant (ABI)

  • Information on the LINK Centre for Deafened People

  • The hearing therapist

  • Tinnitus

  • Understanding balance in Nf2

Factsheets covering both Nf1 and Nf2

  • Membership information

  • The role of the Nf Specialist Advisor

  • How to get the best out of your health professional

  • Pain management

  • The CT scan

  • The MRI scan

  • The PET scan

 

 
 

National Doodle Day is supported by
Lloyds Pharmacy, your local health authority

email a friend about this page · downloadable stuff

Epilepsy Action logo
National Doodle Day is wholly owned by The Neurofibromatosis Association, a registered charity in England (No 1078790), and Epilepsy Action, a working name of British Epilepsy Association, a registered charity in England (No 234343). All monies raised by National Doodle Day will support the work of the two charities.
Neurofibromatosis Association logo

website terms and conditions